J&J reported second quarter earnings Tuesday. The company is under scrutiny by investors as it faces drug patent cliffs.

J&J reported second quarter earnings Tuesday. The company is under scrutiny by investors as it faces drug patent cliffs.

For CVS, Q2 earnings will be a critical inflection point. A miss could trigger a breakup or further decline, making the stock ...

From Medicare myths to 401k confusion, Americans are making costly retirement mistakes. Gavin Newsom's warning to Donald ...

A new report from Gimme Credit's Senior Bond Analyst, Terri Cancelarich highlights growing pressures facing U.S. health ...

(PLD) on Wednesday reported a key measure of profitability in its second quarter. The results beat Wall Street expectations.

UnitedHealth extended its 15-year earnings beat streak in 2024 with $3.3 billion in asset sales, raising questions about ...

We are reminded of the excesses of the “defund the police” and “abolish ICE” movements on the other side of the ideological ...

The final adjustment won’t be confirmed until October, after the Bureau of Labor Statistics releases inflation data for July, August and September. But the recent bump continues a trend: The Senior ...

Analysts have recently evaluated Humana and provided 12-month price targets. The average target is $280.75, accompanied by a ...

We don't have any loans or long-term debt. Our house is worth $500,000 and our cars are paid off. We pay our credit cards in full every month. The children are grown up but our daughter is in medical ...

Rehab hospitals that help people recover from major surgeries and injuries have become a highly lucrative slice of the ...